Exide Industries Ltd EXIDEIND

Summary

Exide Industries is India's largest lead-acid battery maker, and — as of 23 September 2026, six days before this report's research date — it is also the company that has turned a Chinese cell-technology licence into a commissioned lithium-ion plant. Exide signed its technical collaboration agreement with China's SVOLT Energy Technology in March 2022, well before Beijing's technology-transfer environment began tightening; Exide Energy Solutions Ltd (EESL, a wholly-owned subsidiary) has since commissioned Phase-I of a 6 GWh cell plant at Devanahalli, near Bengaluru — 3 GWh of NMC cylindrical capacity and 3 GWh of LFP prismatic capacity — with commercial revenue guided from Q3 FY27. Cylindrical cells are reportedly reaching customer sample-delivery stage with two-wheeler OEMs by Q1 FY27, and equipment setup was reported complete as of August 2026. Against this, the core lead-acid business remains overwhelmingly the revenue base: FY26 consolidated revenue reached ₹17,269 crore with a zero-debt balance sheet and [ICRA]AAA(Stable)/A1+ ratings, and management has separately guided lead-acid revenue alone to ₹20,000 crore within two to three years.

The contrast with this report's other Chinese-technology stories is instructive. Amara Raja's Gotion licensing deal, signed in June 2024 — after China's tightening had already begun — has since stalled; Reliance's Hithium talks reportedly collapsed in January 2026; JSW's flagship Odisha cell project was shelved in August 2026 for lack of an LFP technology partner. Exide's SVOLT relationship, signed two years earlier, is the one visible counter-example in this report of a licence that survived contact with the export-restriction environment this primer's §4 and §7 describe — though no source found in this research explicitly confirms the SVOLT relationship itself has been unaffected by the broader tightening, and the plant's ramp to full commercial revenue is still ahead, not behind.

Cumulative equity investment into EESL had reached ₹4,902 crore as of July 2026, funded entirely from Exide's own zero-debt balance sheet via a series of rights-issue infusions — a materially different funding posture from several peers in this report who are relying on dilutive external capital raises for their own build-outs. Analyst coverage is broadly constructive but not uniformly so: Nomura (Buy, target raised to ₹492) and JM Financial (Buy, ₹450) sit alongside Kotak (Neutral, ₹420) and a reported Nuvama downgrade to Reduce, with a consensus average clustering in the ₹368-438 range — most of it dated before the September 2026 Phase-I commissioning.

Net: BUY. This is a thin-margin call — Exide's core lead-acid business alone does not obviously justify a re-rating — but it is the one company in this report that has actually crossed the "hard half" of this primer's central asymmetry, on a zero-debt, top-rated balance sheet, with commercial revenue about to begin. We size the call to reflect that the ramp is proven to exist, not yet proven to be profitable at scale.

• The only commissioned, technology-transferred Li-ion cell plant in this report's coverage list. EESL's 6 GWh Devanahalli Phase-I (3 GWh NMC cylindrical + 3 GWh LFP prismatic) was commissioned 23 September 2026, with commercial revenue guided from Q3 FY27 — a working plant, not an announcement.
• The technology licence was signed before the access window tightened. The March 2022 SVOLT deal predates by more than two years the wave of Chinese technology-transfer restrictions that have since stalled Amara Raja's, Reliance's and JSW's own cell-technology ambitions (§9 of this primer).
• Funded from a zero-debt, AAA-rated balance sheet. Cumulative ₹4,902cr equity investment into EESL has come entirely from Exide's own rights-issue infusions — no external dilution, no project debt disclosed at the parent level.
• Real, near-term customer engagement. Reported advanced discussions with two-wheeler OEMs for cylindrical NMC cells, with customer sample deliveries guided by Q1 FY27, and advanced discussions for LFP supply to the three-wheeler segment.
• The core lead-acid business is not standing still. Management's own ₹20,000cr-in-2-3-years lead-acid revenue ambition (May 2025) means the Li-ion ramp is genuinely additive, not a distraction from a declining base business.
• Expandability is already engineered in. Phase-I's 6 GWh is explicitly a step toward a planned 12 GWh facility, giving a clear, disclosed path for the ramp to continue if commercial results validate it.

• The ramp is proven to exist, not yet proven to be profitable. Phase-I commissioning (Sep 2026) to guided commercial revenue (Q3 FY27) is a compressed window, and customer qualification for 2W OEM cylindrical cells was only reaching "sample delivery" stage as of the most recent guidance.
• The valuation is not obviously cheap on the core business alone. A ~30-33x trailing multiple (sources disagree on the precise figure) already reflects some expectation of the Li-ion ramp succeeding.
• Large, well-capitalised competitors are entering the same space. Reliance's battery gigafactory programme (targeting 40 GWh initial phase), Tata's Agratas (20 GWh, Sanand), and Amara Raja's own gigafactory (delayed but still planned) all compete for the same customer base EESL is now courting.
• No Exide-specific confirmation was found that the SVOLT relationship itself remains unaffected by the broader Chinese technology-transfer tightening described in §7 of this primer — the plant exists, but whether SVOLT-linked equipment, components or further technology transfer face any of the friction reported for Amara Raja/Gotion was not addressed in any source found.
• Analyst sentiment is mixed, not uniformly bullish. Nomura and JM Financial are constructive, but Kotak sits at Neutral and a Nuvama downgrade to Reduce was reported — average targets found in this research (₹368-438) sit below our own base case, mostly on pre-commissioning data.
• An unresolved trademark dispute with Amara Raja (the "red colour" case) saw Exide win injunctive relief at the Calcutta High Court (Jul 2025); Amara Raja's appeal was heard through Feb 2026 with judgment delivered 2 April 2026 — the outcome of that appellate judgment could not be confirmed in this research.

• Q3 FY27 commercial Li-ion revenue. The single clearest near-term proof point for whether the Devanahalli ramp is translating into P&L impact.
• Named 2W/3W OEM customer wins. Confirmation of specific customers beyond the currently-anonymous "two leading 2W OEMs" reported in advanced discussion.
• Resolution of the Amara Raja trademark appeal — judgment delivered 2 April 2026, outcome unconfirmed in this research.
• Any disclosed progress toward the 12 GWh expansion, which would signal management's own confidence in Phase-I's commercial results.

• Ramp-execution risk (dominant). The gap between "commissioned" and "commercially proven at scale" is where this call could be wrong.
• Competitive risk. Several much larger-scale entrants (Reliance, Tata/Agratas) are building capacity aimed at the same demand.
• Input-cost risk. Rising Chinese cell/cathode prices affect EESL's own cost base during the ramp, not just its competitors'.
• Valuation risk. The current multiple already assumes reasonable execution; a stumble would likely be repriced quickly.

FY26 PAT of ₹1,111cr on an implied share count of ~85.6cr (market cap ÷ CMP) gives FY26 EPS of ~₹12.99. We construct an FY27E EPS of ~₹15.33 using an indicative 18% growth assumption — reflecting continued core lead-acid growth plus an initial, partial-year Li-ion commercial contribution from Q3 FY27 — not management guidance. We apply a target multiple in line with, not above, the current trading range, since the Li-ion ramp's commercial success is not yet proven:

Base case rounded to ₹490. EV/EBITDA cross-check not performed at full precision — Exide's zero-debt status simplifies this (no net-debt adjustment required), but a formal cross-check multiple was not derived in this research pass. Third-party targets found (Nomura ₹492, JM Financial ₹450, Kotak ₹420 Neutral, a reported Nuvama Reduce downgrade) sit on both sides of our own base case and mostly predate the 23 September 2026 commissioning; our target is broadly in line with the more constructive end of that range.

Balance sheet and cash-flow statements are not reproduced here at full granularity beyond the zero-debt status disclosed above. Source: WebSearch aggregation of company disclosures and news coverage, 29 Sep 2026, reflecting a share-price snapshot dated 25 Sep 2026.